See more : BellRock Brands Inc. (DXBRF) Income Statement Analysis – Financial Results
Complete financial analysis of Hemogenyx Pharmaceuticals Plc (HOPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemogenyx Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aquarius Engines (A.M) Ltd. (AQUA.TA) Income Statement Analysis – Financial Results
- African Rainbow Capital Investments Limited (AIL.JO) Income Statement Analysis – Financial Results
- Rio Silver Inc. (RYO.V) Income Statement Analysis – Financial Results
- Ganesh Benzoplast Limited (GANESHBE.BO) Income Statement Analysis – Financial Results
- Qingdao Vland Biotech INC. (603739.SS) Income Statement Analysis – Financial Results
Hemogenyx Pharmaceuticals Plc (HOPHF)
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85K | 0.00 |
| Cost of Revenue | 645.68K | 2.60M | 283.65K | 350.72K | 421.82K | 348.27K | 100.48K | 66.86K | 0.00 | 0.00 |
| Gross Profit | -645.68K | -2.60M | -283.65K | -350.72K | -421.82K | -348.27K | -100.48K | -66.86K | 6.85K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 90.63K | 487.10 | 50.82 | 114.41 | 28.14 | 73.50 | 18.96 | 2.00 | 0.00 | 0.00 |
| General & Administrative | 4.91M | 942.35K | 1.40M | 623.84K | 429.07K | 402.98K | 390.66K | 331.59K | 174.30K | 6.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.22K | 33.51K | 14.63K | 19.49K | 80.40K | 3.54 | 0.00 |
| SG&A | 4.91M | 942.35K | 1.40M | 628.06K | 462.58K | 417.61K | 410.16K | 411.99K | 176.70K | 6.27K |
| Other Expenses | 1.46M | 0.00 | 0.00 | 85.24K | 213.13K | 91.36K | 101.14K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.47M | 2.93M | 2.55M | 1.87M | 1.25M | 1.26M | 690.69K | 411.99K | 176.70K | 6.27K |
| Cost & Expenses | 6.47M | 5.53M | 2.83M | 2.22M | 1.67M | 1.61M | 791.17K | 411.99K | 176.70K | 6.27K |
| Interest Income | 85.34K | 10.60K | 17.96K | 3.37K | 14.19K | 4.37K | 14.50 | 14.56 | 16.25 | 0.00 |
| Interest Expense | 315.99K | 33.00 | 2.60M | 33.24K | 31.33K | 1.78K | 10.74K | 11.82K | 0.00 | 0.00 |
| Depreciation & Amortization | 225.40K | 564.07K | 126.34K | 106.75K | 94.73K | 51.81K | 33.61K | 11.87K | 169.86K | 0.00 |
| EBITDA | -5.33M | -5.44M | -2.56M | -2.08M | -1.63M | -1.63M | -837.06K | -447.15K | -0.59 | -6.27K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.97% | 0.00% |
| Operating Income | -6.47M | 4.00M | -2.70M | -2.15M | -1.68M | -1.62M | -820.98K | -519.90K | -169.86K | -6.27K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,481.32% | 0.00% |
| Total Other Income/Expenses | -230.65K | 10.57K | -2.41M | 55.36K | 195.99K | 27.16K | -1.49M | -11.82K | -11.02K | 0.00 |
| Income Before Tax | -6.70M | -3.99M | -5.11M | -2.10M | -1.49M | -1.52M | -2.36M | -519.90K | -180.88K | -6.27K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| Income Tax Expense | 0.00 | 361.20K | 2.41M | 20.51K | -35.00K | -43.75K | 67.10 | 215.78K | -16.25 | 0.00 |
| Net Income | -6.69M | -3.98M | -5.10M | -2.08M | -1.45M | -1.48M | -2.36M | -519.90K | -180.88K | -6.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
| Weighted Avg Shares Out (Dil) | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
Hemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial Opening
Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1) LONDON, UK / ACCESSWIRE / October 30, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a biopharmaceutical company focused on developing breakthrough therapies for blood diseases,...
Hemogenyx Pharmaceuticals up 9% after it receives further investment from partner Prevail
Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) rose 9% after it secured a new $350,000 investment from Prevail Partners, an investment fund, as it gears up for important clinical trials. The investment, which comes at a price significantly above the company's current...
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Prevail Partners, LLC to invest again in Hemogenyx Pharmaceuticals Prevail InfoWorks, Inc. to act as Clinical Research Organization (CRO) for upcoming Phase I pediatric clinical study LONDON, UNITED KINGDOM / ACCESSWIRE / October 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO),...
Hemogenyx Pharmaceuticals readies for phase I trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) confirmed it is in the final stages of opening a clinical site ahead of a phase I trial of its lead asset, HEMO-CAR-T, which is being developed to treat acute myeloid leukaemia (AML). In an update...
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces...
Hemogenyx Pharmaceuticals passes crucial milestone ahead of phase I trial
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has developed a clinical-grade assay to measure FLT3 protein levels in acute myeloid leukaemia (AML) cells. This test is essential for selecting patients for the upcoming phase I clinical trials of its HEMO-CAR-T treatment, which will...
Hemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD Anderson
LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce the successful completion of the development of a clinical-grade...
Hemogenyx Pharmaceuticals hails potential of new CDX antibody
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) has announced the development of a new version of its bi-specific CDX antibody aimed at treating relapsed or refractory acute myeloid leukaemia (AML), which also shows potential for use in bone marrow transplant conditioning. The...
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it...
Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference
LONDON, UNITED KINGDOM / ACCESSWIRE / August 28, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 2024 Chemical and Biological Defense Science &...
Source: https://incomestatements.info
Category: Stock Reports